Deals Shaping The Medical Industry, December 2014
Executive Summary
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced October-November 2014.
You may also be interested in...
The Next Big PBM Deal? Rumored Cigna-Humana Talks Raise Overlap Question
Vigorous regulatory scrutiny is a given, but opinions vary about how much the companies’ respective PBM businesses present a major antitrust risk.
Clinical Trial Diversity Plans: Early Oncology Experience Shows More Work Needed, US FDA Says
Few plans submitted to FDA’s oncology review divisions in the wake of the April 2022 draft guidance were deemed acceptable, with enrollment goals being the most common topic of agency feedback. However, representatives from FDA and industry say the regulatory demand for such plans is pushing sponsors to build diversity into clinical trial programs from the start.
FDA’s Bumpus Will Be Principal Deputy Commissioner; Cosmetics Industry Reacts With Congratulations, Questions
Chief scientist Namandjé Bumpus will replace Janet Woodcock as principal deputy commissioner at the US FDA when the latter steps down in early 2024. The Personal Care Products Council says Bumpus will continue to lead MoCRA implementation efforts while a new chief scientist is sought, but those and other details remain fuzzy.